The Principle of Rational Design of Drug Combination and Personalized Therapy Based on Network Pharmacology
Systems Biology in Cancer Research and Drug Discovery, Page: 325-337
2012
- 1Citations
- 7Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Network Pharmacology attempts to model the effects of drug action by simultaneously modulating multiple components in a gene network. However, the theoretical basis for this new concept is still in its infancy and the process by which we translate network modeling to clinical application remains indirect. In this chapter, we try to outline the principles of rational designs for drug combination and personalized therapy based on network pharmacology by deciphering several milestone examples. We demonstrate that the network, which characterizes the dependency or joint dependency between genes and disease phenotype, is the key battle map for rational drug combinations and design of personalized therapy. We also tentatively outline several aspects of the process which might help drive innovation in network construction and shape the future development of network pharmacology applications.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84875047014&origin=inward; http://dx.doi.org/10.1007/978-94-007-4819-4_14; http://link.springer.com/10.1007/978-94-007-4819-4_14; http://link.springer.com/content/pdf/10.1007/978-94-007-4819-4_14; https://dx.doi.org/10.1007/978-94-007-4819-4_14; https://link.springer.com/chapter/10.1007/978-94-007-4819-4_14
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know